Lucid Historical Financial Ratios
| LUCD Stock | USD 0.79 0.02 2.60% |
Lucid Diagnostics is lately reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Invested Capital of 0.0 will help investors to properly organize and evaluate Lucid Diagnostics financial condition quickly.
Lucid |
About Lucid Financial Ratios Analysis
Lucid DiagnosticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Lucid Diagnostics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Lucid financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Lucid Diagnostics history.
Lucid Diagnostics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Lucid Diagnostics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lucid Diagnostics sales, a figure that is much harder to manipulate than other Lucid Diagnostics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Lucid Diagnostics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.At present, Lucid Diagnostics' Net Debt To EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Graham Number is expected to grow to 1.80, whereas Book Value Per Share is projected to grow to (0.05).
| 2010 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.39 | 3.42 | 5.22 | 5.48 | Days Of Inventory On Hand | 307.6 | 11.21 | 16.97 | 16.12 |
Lucid Diagnostics fundamentals Correlations
Click cells to compare fundamentals
Lucid Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lucid Diagnostics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (81.94) | (32.18) | 3.43 | 2.13 | (25.48) | (26.75) | |
| Book Value Per Share | (0.14) | (0.37) | 1.57 | 0.64 | (0.0553) | (0.0526) | |
| Free Cash Flow Yield | (0.005428) | (0.0129) | (0.0988) | (0.62) | (0.56) | (0.53) | |
| Operating Cash Flow Per Share | (0.0638) | (0.15) | (0.51) | (0.82) | (0.79) | (0.83) | |
| Pb Ratio | (81.94) | (32.18) | 3.43 | 2.13 | (25.48) | (26.75) | |
| Free Cash Flow Per Share | (0.0638) | (0.15) | (0.53) | (0.85) | (0.79) | (0.83) | |
| Roic | (1.0E-6) | (3.5E-5) | (0.51) | (2.51) | (4.17) | (3.96) | |
| Net Income Per Share | (0.12) | (0.22) | (0.82) | (1.55) | (1.26) | (1.32) | |
| Cash Per Share | 0.00742 | 0.006197 | 1.57 | 0.66 | 0.45 | 0.36 | |
| Pocfratio | (184.22) | (77.29) | (10.61) | (1.66) | (1.79) | (1.88) | |
| Pfcf Ratio | (184.22) | (77.29) | (10.12) | (1.61) | (1.78) | (1.87) | |
| Roe | 0.83 | 0.61 | (0.52) | (2.44) | 22.79 | 23.93 | |
| Ev To Operating Cash Flow | (184.16) | (77.27) | (7.58) | (0.97) | (1.68) | (1.77) | |
| Pe Ratio | (98.41) | (52.54) | (6.53) | (0.88) | (1.12) | (1.17) | |
| Return On Tangible Assets | (4.28) | (3.77) | (0.49) | (1.93) | (2.04) | (2.14) | |
| Ev To Free Cash Flow | (184.16) | (77.27) | (7.22) | (0.94) | (1.67) | (1.76) | |
| Earnings Yield | (0.0102) | (0.019) | (0.15) | (1.14) | (0.89) | (0.85) | |
| Current Ratio | 0.0616 | 0.0916 | 13.45 | 2.89 | 0.75 | 0.71 | |
| Tangible Book Value Per Share | (0.14) | (0.37) | 1.57 | 0.54 | (0.0894) | (0.085) | |
| Graham Number | 0.62 | 1.36 | 5.39 | 4.72 | 1.25 | 1.8 | |
| Shareholders Equity Per Share | (0.14) | (0.37) | 1.57 | 0.64 | (0.0553) | (0.0526) | |
| Graham Net Net | (0.16) | (0.41) | 1.46 | 0.4 | (0.25) | (0.24) | |
| Price Earnings Ratio | (98.41) | (52.54) | (6.53) | (0.88) | (1.12) | (1.17) | |
| Price Book Value Ratio | (81.94) | (32.18) | 3.43 | 2.13 | (25.48) | (26.75) | |
| Price To Operating Cash Flows Ratio | (184.22) | (77.29) | (10.61) | (1.66) | (1.79) | (1.88) | |
| Price To Free Cash Flows Ratio | (184.22) | (77.29) | (10.12) | (1.61) | (1.78) | (1.87) | |
| Company Equity Multiplier | (0.19) | (0.16) | 1.08 | 1.41 | (11.8) | (11.21) | |
| Return On Capital Employed | 0.83 | 0.61 | (0.5) | (2.33) | 22.96 | 24.1 | |
| Quick Ratio | 0.0616 | 0.0386 | 13.34 | 2.88 | 0.74 | 0.7 | |
| Cash Ratio | 0.0247 | 0.00708 | 12.6 | 2.67 | 0.64 | 0.61 | |
| Price To Book Ratio | (81.94) | (32.18) | 3.43 | 2.13 | (25.48) | (26.75) | |
| Price Cash Flow Ratio | (184.22) | (77.29) | (10.61) | (1.66) | (1.79) | (1.88) | |
| Return On Assets | (4.28) | (3.77) | (0.49) | (1.73) | (1.93) | (2.03) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.